Methods of O-demethylation and N-deprotection
    1.
    发明授权
    Methods of O-demethylation and N-deprotection 失效
    O-去甲基化和N-去保护的方法

    公开(公告)号:US06395900B1

    公开(公告)日:2002-05-28

    申请号:US09895956

    申请日:2001-06-29

    IPC分类号: C07D48902

    摘要: The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.

    摘要翻译: 本发明提供了对阿片样物质进行N-去保护的方法,对于阿片样物质进行N-脱保护和O-脱甲基化的方法,对阿片样物质进行O-去甲基化的方法,以及将非肽δ激动剂化合物O-脱甲基化的方法 或具有在酰胺基上没有显着反应的叔酰胺的阿片样物质化合物。

    Methods of o-demethylation and n-deprotection
    2.
    发明授权
    Methods of o-demethylation and n-deprotection 失效
    去甲基化和去脱保护的方法

    公开(公告)号:US06291675B1

    公开(公告)日:2001-09-18

    申请号:US09194510

    申请日:1999-07-06

    IPC分类号: C07D48902

    摘要: The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.

    摘要翻译: 本发明提供了对阿片样物质进行N-去保护的方法,对于阿片样物质进行N-脱保护和O-脱甲基化的方法,对阿片样物质进行O-去甲基化的方法,以及将非肽δ激动剂化合物O-脱甲基化的方法 或具有在酰胺基上没有显着反应的叔酰胺的阿片样物质化合物。

    NOVEL MIXED μ AGONIST/ δ ANTAGONIST OPIOID ANALGESICS WITH REDUCED TOLERANCE LIABILITIES AND USES THEREOF
    3.
    发明申请
    NOVEL MIXED μ AGONIST/ δ ANTAGONIST OPIOID ANALGESICS WITH REDUCED TOLERANCE LIABILITIES AND USES THEREOF 有权
    新型混合μAGONIST /δANTAGONIST OPIOID ANALGESICS具有降低的容忍负荷及其用途

    公开(公告)号:US20160016965A1

    公开(公告)日:2016-01-21

    申请号:US14772592

    申请日:2014-03-06

    IPC分类号: C07D489/08 C07D489/02

    CPC分类号: C07D489/08 C07D489/02

    摘要: An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects. The present invention includes 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor, along with analogs of morphine, dihydromorphine, hydromorphone, codeine, dihydrocodeine, hydrocodone and ethylmorphine. Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compound sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols. UMB 425 exhibits a mixed μ agonist/δ antagonist profile as determined in receptor binding. UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.

    摘要翻译: 用于治疗主要通过μ受体发挥其镇痛作用的中度至重度疼痛的阿片样麻醉药物。 尽管传统的μ激动剂可能引起不希望的副作用,包括耐受性,δ拮抗剂的添加可以减弱所述副作用。 本发明包括4a,9-二羟基-7a-(羟甲基)-3-甲基-2,3,4,4a,5,6-六氢-1H-4,12-甲基苯并呋喃并[3,2-e] 7(7aH) - 酮(UMB 425)5,14-桥连的吗啡喃基的月桂醇前体,以及吗啡,二氢吗啡,氢吗啡酮,可待因,二氢可待因,氢可酮和乙基吗啡的类似物。 虽然UMB 425缺乏δ特异性基序,但是构象取样的μ和δ受体的药效团模型预测其在μ受体上具有与吗啡相似的功效,并且与δ受体的纳曲酮类似,这是由于羟基部分与 类似于orvinols的受体。 UMB 425显示在受体结合中测定的混合μ激动剂/δ拮抗剂谱。 UMB 425在体外具有混合的μ激动剂/δ拮抗剂性质,其在体内转化为降低的耐受负荷。

    Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
    5.
    发明申请
    Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands 有权
    3-羟基苯乙酸的醚作为选择性γ-羟基丁酸受体配体

    公开(公告)号:US20070197650A1

    公开(公告)日:2007-08-23

    申请号:US11707120

    申请日:2007-02-16

    IPC分类号: A61K31/192

    CPC分类号: A61K31/192

    摘要: The present invention generally relates to pharmaceutical compositions comprising ethers of 3-hydroxyphenylacetic acid. The present invention also relates to therapeutic uses of the ethers of 3-hydroxyphenylacetic acid. The ethers of 3-hydroxyphenylacetic acid have the chemical structural of formula (I): where R is an aromatic or arylalkyl substituent.

    摘要翻译: 本发明一般涉及包含3-羟基苯基乙酸醚的药物组合物。 本发明还涉及3-羟基苯基乙酸的醚的治疗用途。 3-羟基苯基乙酸的醚具有式(I)的化学结构:其中R是芳族或芳烷基取代基。